⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for brca1 mutation

Every month we try and update this database with for brca1 mutation cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
A Study on Association Between HR Genes and the HRD Status in Chinese Epithelial Ovarian CancerNCT04651920
Epithelial Ovar...
Chinese
Homologous Reco...
BRCA1 Mutation
BRCA2 Mutation
Prognosis
Homologous Reco...
Evaluation of h...
18 Years - Peking Union Medical College Hospital
HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast CancerNCT03685331
Metastatic Brea...
Locally Advance...
Advanced Breast...
BRCA2 Mutation
BRCA1 Mutation
Palbociclib
Olaparib
Fulvestrant
18 Years - Abramson Cancer Center at Penn Medicine
Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid TumorsNCT06065059
Breast Cancer
Ovarian Cancer
Pancreas Cancer
Prostate Cancer
BRCA1 Mutation
BRCA-Mutated Ov...
BRCA-Associated...
HRD Positive Ad...
TNG348
Olaparib
18 Years - Tango Therapeutics, Inc.
Depression and Body Image Distress Following Mastectomy With ReconstructionNCT03428399
Breast Cancer
BRCA1 Mutation
BRCA2 Mutation
Psychosocial va...
18 Years - Massachusetts General Hospital
Combination Therapy in Cancers With Mutations in DNA Repair GenesNCT05694715
Metastatic Soli...
BRCA1 Mutation
BRCA2 Mutation
ATM Gene Mutati...
PALB2 Gene Muta...
Niraparib
Irinotecan
18 Years - University of California, San Francisco
Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With BRCA1/2 Gene AlterationsNCT05498272
Prostate Cancer
BRCA1 Mutation
BRCA2 Mutation
Prostatic Adeno...
High-Risk Cance...
Olaparib
LHRH agonist
18 Years - Hoosier Cancer Research Network
Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast CancerNCT05485766
Triple Negative...
Triple Negative...
Breast Neoplasm...
Breast Cancer
BRCA1 Mutation
BRCA2 Mutation
BRCA Mutation
BRCA-Associated...
Pembrolizumab
Paclitaxel
Carboplatin
Olaparib
Definitive Surg...
18 Years - Okayama University
Efficacy of Platinum-based Chemotherapy in Platinum-resistant Ovarian Cancer) (EPITOC)NCT04055038
Ovarian Cancer
Ovarian Neoplas...
Serous Adenocar...
BRCA1 Mutation
BRCA2 Mutation
Chemotherapy
Platinum-Based ...
Conventional ch...
18 Years - 70 YearsBlokhin's Russian Cancer Research Center
Prostate Cancer Genetic Risk Evaluation and Screening StudyNCT05129605
Prostatic Neopl...
Prostate Cancer
BRCA2 Mutation
BRCA1 Mutation
ATM Gene Mutati...
MMR Mutation
Lynch Syndrome
Genetic Predisp...
Prostate cancer...
35 Years - 74 YearsMassachusetts General Hospital
Interest of Broadband Spectroscopy Analysis by Infrared Laser on Liquid Biopsies in Breast Cancer ScreeningNCT04273542
Breast Cancer F...
BRCA1 Mutation
BRCA2 Mutation
liquid biopsy
18 Years - Centre Jean Perrin
Combination of Olaparib and Navitoclax in Women With HGSC and TNBCNCT05358639
High Grade Sero...
Triple Negative...
Ovarian Cancer
Olaparib tablet
Navitoclax
18 Years - Sunnybrook Health Sciences Centre
Veliparib Monotherapy for Relapsed Ovarian Cancer With BRCA MutationNCT01472783
Recurrent, Epit...
Veliparib
18 Years - Vejle Hospital
IMpact of Breast cAncer Gene Status on Survival in Adjuvant Breast Cancer (IMBASSA)NCT04012229
Breast Cancer
BRCA1 Mutation
BRCA2 Mutation
BRCA mutation
18 Years - Centre Hospitalier Universitaire de Besancon
Longitudinal Sample Collection to Investigate Adaptation and Evolution of Ovarian High-grade Serous CarcinomaNCT05537844
Ovarian Cancer
High Grade Sero...
Carcinosarcoma,...
Fallopian Tube ...
Primary Periton...
BRCA1 Mutation
BRCA2 Mutation
16 Years - Cancer Research UK, Glasgow
Genetic Education in BRCA FamiliesNCT03544983
BRCA1 Mutation
BRCA2 Mutation
Web + Streamlin...
21 Years - 75 YearsGeorgetown University
IMpact of Breast cAncer Gene Status on Survival in Adjuvant Breast Cancer (IMBASSA)NCT04012229
Breast Cancer
BRCA1 Mutation
BRCA2 Mutation
BRCA mutation
18 Years - Centre Hospitalier Universitaire de Besancon
Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated TumorsNCT06177171
BRCA1 Mutation
BRCA2 Mutation
BRCA Mutation
PALB2 Gene Muta...
Checkpoint Kina...
ATM Gene Mutati...
Olaparib
ASTX727
18 Years - University of California, San Francisco
Decision Support for BRCA Testing in Ethnically Diverse WomenNCT03470402
Breast Cancer
BRCA1 Mutation
BRCA2 Mutation
Ovarian Cancer
RealRisks
BNAV
iNYP
Standard Educat...
High-Risk Messa...
21 Years - 75 YearsColumbia University
Combination of Olaparib and Navitoclax in Women With HGSC and TNBCNCT05358639
High Grade Sero...
Triple Negative...
Ovarian Cancer
Olaparib tablet
Navitoclax
18 Years - Sunnybrook Health Sciences Centre
Study to Evaluate Treatment Customized According to RAP80 and BRCA1 in Patients With Advanced Lung CarcinomaNCT00617656
Non Small Cell ...
BRCA1 Mutation
Cisplatin, Doce...
Gemcitabine, Ci...
Docetaxel, Cisp...
Docetaxel
18 Years - Spanish Lung Cancer Group
Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid TumorsNCT06065059
Breast Cancer
Ovarian Cancer
Pancreas Cancer
Prostate Cancer
BRCA1 Mutation
BRCA-Mutated Ov...
BRCA-Associated...
HRD Positive Ad...
TNG348
Olaparib
18 Years - Tango Therapeutics, Inc.
Abbreviated Breast MRI for Second Breast Cancer Detection in Women With BRCA Mutation TestingNCT03475979
Breast Cancer
BRCA1 Mutation
BRCA2 Mutation
Recurrent Breas...
Metachronous Ne...
25 Years - 75 YearsSeoul National University Hospital
Health After eaRly Menopause Due to OophorectomyNCT03835793
Surgical Menopa...
BRCA1 Mutation
BRCA2 Mutation
Cardiovascular ...
Bone Mineral De...
Cognitive Decli...
Quality of Life
Menopause Surgi...
CAC-score
55 Years - The Netherlands Cancer Institute
Chemo-free BRCA-targeted Neoadjuvant StrategyNCT05209529
TNBC - Triple-N...
BRCA1 Mutation
BRCA2 Mutation
olaparib
Durvalumab
18 Years - European Organisation for Research and Treatment of Cancer - EORTC
Study of ACE-86225106 to Treat Patients With Advanced Solid TumorsNCT06380660
Solid Tumor, Ad...
BRCA1 Mutation
BRCA2 Mutation
Ovarian Cancer
Breast Cancer
Prostate Cancer
ACE-86225106 ta...
18 Years - Acerand Therapeutics Limited
Pre-Salpingo-Oophorectomy Pilot Study of MAKO 7 Device PerformanceNCT02974842
BRCA1 Mutation
BRCA2 Mutation
Atypia Suspicio...
MAKO 7
18 Years - nVision Medical
3.0 Tesla Magnetic Resonance Imaging for Breast Cancer Detection in High Risk WomenNCT01409226
Breast Cancer
BRCA1 Mutation
BRCA2 Mutation
3.0-T MRI
biopsy
18 Years - 70 YearsNYU Langone Health
Studying the Effect of Denosumab on Preventing Breast Cancer in Women With a BRCA1 Germline MutationNCT04711109
BRCA1 Mutation
Breast Cancer
Breast Diseases
Breast Neoplasm...
Breast Carcinom...
Neoplasms
Denosumab
Placebo
Quality-of-Life...
25 Years - 55 YearsAlliance for Clinical Trials in Oncology
Recombinant Human Chorionic Gonadotropin in Preventing Breast Cancer in Premenopausal Women With BRCA1 MutationsNCT00700778
BRCA1 Mutation
Breast Cancer
recombinant hum...
microarray anal...
immunohistochem...
laboratory biom...
needle biopsy
20 Years - 40 YearsFox Chase Cancer Center
Longitudinal Sample Collection to Investigate Adaptation and Evolution of Ovarian High-grade Serous CarcinomaNCT05537844
Ovarian Cancer
High Grade Sero...
Carcinosarcoma,...
Fallopian Tube ...
Primary Periton...
BRCA1 Mutation
BRCA2 Mutation
16 Years - Cancer Research UK, Glasgow
A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair DeficiencyNCT02873975
Advanced Cancer...
LY2606368
18 Years - Dana-Farber Cancer Institute
Effect of Counseling on Psychological Stress Amongst Women Felt to be at High Risk for Breast Cancer DevelopmentNCT00381927
Breast Cancer
Physician Couns...
18 Years - Baystate Medical Center
Efficacy of Platinum-based Chemotherapy in Platinum-resistant Ovarian Cancer) (EPITOC)NCT04055038
Ovarian Cancer
Ovarian Neoplas...
Serous Adenocar...
BRCA1 Mutation
BRCA2 Mutation
Chemotherapy
Platinum-Based ...
Conventional ch...
18 Years - 70 YearsBlokhin's Russian Cancer Research Center
Cisplatin-monotherapy in the Treatment of BRCA1 Positive Breast Cancer Patients in PolandNCT01630226
BRCA1 Mutation
Breast Cancer I...
Neoadjuvant Cis...
20 Years - 70 YearsPomeranian Medical University Szczecin
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 MutationNCT04858334
Pancreatic Acin...
Pancreatic Aden...
Pancreatic Squa...
Resectable Panc...
Resectable Panc...
Resectable Panc...
Resectable Panc...
Biospecimen Col...
Computed Tomogr...
Magnetic Resona...
Olaparib
Placebo Adminis...
18 Years - National Cancer Institute (NCI)
Functional Analysis of BRCAnessNCT04780945
Ovarian Neoplas...
Homologous Reco...
BRCA1 Mutation
BRCA2 Mutation
Functional RAD5...
Olaparib Oral P...
18 Years - Leiden University Medical Center
Botulinum Toxin A (Botox) in Tissue Expander Breast ReconstructionNCT01591746
Breast Cancer
Pain, Postopera...
BRCA1 Mutation
BRCA2 Mutation
Breast Diseases
Neoplasms
Botulinum Toxin...
Placebo
18 Years - Mayo Clinic
The GENPET Study - An Imaging Study of FCH-PET-CT in Men With Prostate Cancer and a BRCA Gene Mutation.NCT05097274
Prostate Cancer
BRCA1 Mutation
BRCA2 Mutation
MRI pelvis or C...
Whole body bone...
PET-CT imaging
18 Years - Institute of Cancer Research, United Kingdom
LobularCard Trial: Searching for Novel Germline Mutations in Lobular Breast Cancer PatientsNCT05410951
Lobular Breast ...
Lobular in Situ...
BRCA1 Mutation
BRCA2 Mutation
Illumina panel
18 Years - 99 YearsEuropean Institute of Oncology
Interest of Broadband Spectroscopy Analysis by Infrared Laser on Liquid Biopsies in Breast Cancer ScreeningNCT04273542
Breast Cancer F...
BRCA1 Mutation
BRCA2 Mutation
liquid biopsy
18 Years - Centre Jean Perrin
Circulating Tumor DNA and Follow-up of BRCA1 Mutation Carriers (CirCa 01)NCT02608346
Women With BRCA...
Blood sampling
30 Years - Institut Curie
Recombinant Human Chorionic Gonadotropin in Preventing Breast Cancer in Premenopausal Women With BRCA1 MutationsNCT00700778
BRCA1 Mutation
Breast Cancer
recombinant hum...
microarray anal...
immunohistochem...
laboratory biom...
needle biopsy
20 Years - 40 YearsFox Chase Cancer Center
Efficacy of Platinum-based Chemotherapy in Platinum-resistant Ovarian Cancer) (EPITOC)NCT04055038
Ovarian Cancer
Ovarian Neoplas...
Serous Adenocar...
BRCA1 Mutation
BRCA2 Mutation
Chemotherapy
Platinum-Based ...
Conventional ch...
18 Years - 70 YearsBlokhin's Russian Cancer Research Center
Chemo-free BRCA-targeted Neoadjuvant StrategyNCT05209529
TNBC - Triple-N...
BRCA1 Mutation
BRCA2 Mutation
olaparib
Durvalumab
18 Years - European Organisation for Research and Treatment of Cancer - EORTC
Cisplatin vs. Doxorubicin/Cyclophosphamide in BrCaNCT01670500
Breast Cancer
Cisplatin
Cyclophosphamid...
Doxorubicin
18 Years - Dana-Farber Cancer Institute
Prospective Registry Trial for Single Port Robot-assisted Nipple Sparing Mastectomy (SPrNSM)NCT04866992
Anatomic Stage ...
Anatomic Stage ...
Anatomic Stage ...
Anatomic Stage ...
Anatomic Stage ...
Anatomic Stage ...
Anatomic Stage ...
Ductal Carcinom...
Prognostic Stag...
Prognostic Stag...
BRCA1 Mutation
BRCA2 Mutation
18 Years - University of Texas Southwestern Medical Center
LobularCard Trial: Searching for Novel Germline Mutations in Lobular Breast Cancer PatientsNCT05410951
Lobular Breast ...
Lobular in Situ...
BRCA1 Mutation
BRCA2 Mutation
Illumina panel
18 Years - 99 YearsEuropean Institute of Oncology
Surgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate ReconstructionNCT04108117
Postoperative C...
Recurrence
Breast Neoplasm...
Breast Cancer
BRCA1 Mutation
BRCA2 Mutation
Surgery
Surgery--Compli...
Robotic nipple ...
- Severance Hospital
Homologous Recombination Deficiency Status in Epithelial Ovarian CancerNCT04190667
Epithelial Ovar...
Chinese
Homologous Reco...
BRCA1 Mutation
BRCA2 Mutation
Prognosis
Genomic testing
18 Years - Peking Union Medical College Hospital
IMpact of Breast cAncer Gene Status on Survival in Adjuvant Breast Cancer (IMBASSA)NCT04012229
Breast Cancer
BRCA1 Mutation
BRCA2 Mutation
BRCA mutation
18 Years - Centre Hospitalier Universitaire de Besancon
The Genetic Education for Men Trial: Web-Based Education vs. Standard CareNCT02957981
Prostate Carcin...
Breast Neoplasm
Pancreatic Canc...
BRCA1 Mutation
BRCA2 Mutation
Web-based Couns...
Standard Care
25 Years - 70 YearsGeorgetown University
Cisplatin-monotherapy in the Treatment of BRCA1 Positive Breast Cancer Patients in PolandNCT01630226
BRCA1 Mutation
Breast Cancer I...
Neoadjuvant Cis...
20 Years - 70 YearsPomeranian Medical University Szczecin
The Genetic Education for Men Trial: Web-Based Education vs. Standard CareNCT02957981
Prostate Carcin...
Breast Neoplasm
Pancreatic Canc...
BRCA1 Mutation
BRCA2 Mutation
Web-based Couns...
Standard Care
25 Years - 70 YearsGeorgetown University
Circulating Tumor DNA and Follow-up of BRCA1 Mutation Carriers (CirCa 01)NCT02608346
Women With BRCA...
Blood sampling
30 Years - Institut Curie
Open-Label,Non-Randomized Trial of Cisplatin Chemotherapy in BRCA1-Positive Metastatic Breast Cancer PatientsNCT01611727
BRCA1 Mutation
Metastatic Brea...
Cisplatin
18 Years - Pomeranian Medical University Szczecin
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid MalignanciesNCT06395519
Advanced or Met...
Breast Cancer
Ovarian Cancer
Prostate Cancer
Epithelial Ovar...
BRCA2 Mutation
ER+ Breast Canc...
Castrate Resist...
BRCA1 Mutation
BRCA Mutation
Endometrial Can...
Colorectal Canc...
Gastric Cancer
ETX-19477
18 Years - 858 Therapeutics, Inc.
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 MutationNCT04858334
Pancreatic Acin...
Pancreatic Aden...
Pancreatic Squa...
Resectable Panc...
Resectable Panc...
Resectable Panc...
Resectable Panc...
Biospecimen Col...
Computed Tomogr...
Magnetic Resona...
Olaparib
Placebo Adminis...
18 Years - National Cancer Institute (NCI)
Use of Recombinant hCG to Prevent Breast Cancer in BRCA1 and BRCA2 CarriersNCT03495609
hCG
BRCA1 Mutation
BRCA2 Mutation
Ovitrelle
18 Years - 30 YearsUniversity Hospital, Ghent
Surgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate ReconstructionNCT04108117
Postoperative C...
Recurrence
Breast Neoplasm...
Breast Cancer
BRCA1 Mutation
BRCA2 Mutation
Surgery
Surgery--Compli...
Robotic nipple ...
- Severance Hospital
Circulating Tumor DNA and Follow-up of BRCA1 Mutation Carriers (CirCa 01)NCT02608346
Women With BRCA...
Blood sampling
30 Years - Institut Curie
Radical Fimbriectomy for Young BRCA Mutation CarriersNCT01608074
BRCA1 Mutation
BRCA2 Mutation
Hereditary Brea...
Radical fimbrie...
Histopathology ...
35 Years - Centre Oscar Lambret
Dietary Intervention and BRCA PenetranceNCT03066856
Dietary Modific...
BRCA1 Mutation
BRCA2 Mutation
Breast Cancer
Dietary interve...
18 Years - 70 YearsFondazione IRCCS Istituto Nazionale dei Tumori, Milano
Web-based Family History ToolNCT04890327
Gynecologic Can...
Breast Cancer
BRCA1 Mutation
BRCA2 Mutation
Web-based famil...
18 Years - 100 YearsWeill Medical College of Cornell University
Liquid Biopsy Evaluation and Repository Development at Princess MargaretNCT03702309
Cancer
Breast Cancer
Lung Cancer
Colon Cancer
Ovarian Cancer
Melanoma
Lymphoma
Leukemia
Mutation
Lynch Syndrome
Cowden Syndrome
BRCA1 Mutation
BRCA2 Mutation
Uterine Cancer
Myeloma
Kidney Cancer
Head and Neck C...
Meningioma
18 Years - University Health Network, Toronto
Combination of Olaparib and Navitoclax in Women With HGSC and TNBCNCT05358639
High Grade Sero...
Triple Negative...
Ovarian Cancer
Olaparib tablet
Navitoclax
18 Years - Sunnybrook Health Sciences Centre
Study to Evaluate Treatment Customized According to RAP80 and BRCA1 in Patients With Advanced Lung CarcinomaNCT00617656
Non Small Cell ...
BRCA1 Mutation
Cisplatin, Doce...
Gemcitabine, Ci...
Docetaxel, Cisp...
Docetaxel
18 Years - Spanish Lung Cancer Group
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: